Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11309572 | 0.83 | LMNA (0.41) | LMNACYP3A4ALOX15MEN1MAPK1 | |
| SCHEMBL2446522 | 0.83 | LMNA (0.41) | LMNACYP3A4ALOX15MEN1MAPK1 | |
| SCHEMBL2437290 | 0.82 | LMNA (0.40) | LMNACYP3A4ALOX15MEN1MAPK1 | |
| SCHEMBL2443192 | 0.81 | LMNA (0.39) | LMNACYP3A4ALOX15MEN1MAPK1 | |
| SCHEMBL2441634 | 0.80 | LMNA (0.49) | LMNACYP3A4ALOX15MEN1MAPK1 | |
| SCHEMBL2441495 | 0.78 | LMNA (0.37) | LMNACYP3A4ALOX15MEN1MAPK1 | |
| SCHEMBL21822059 | 0.77 | LMNA (0.37) | LMNACYP3A4ALOX15MEN1MAPK1 | |
| SCHEMBL2439770 | 0.76 | LMNA (0.36) | LMNACYP3A4ALOX15MEN1MAPK1 | |
| SCHEMBL12032240 | 0.76 | LMNA (0.39) | LMNACYP3A4ALOX15MEN1MAPK1 | |
| SCHEMBL15012463 | 0.76 | LMNA (0.42) | LMNACYP3A4ALOX15MEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2362765-B1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2020-04-08 | — | — | EP | claimed |
| CN-102300550-A | Perfume systems | — | 2011-12-28 | — | — | CN | claimed |
| EP-2362765-A2 | PERFUME SYSTEMS | The Procter & Gamble Company (US) | 2011-09-07 | — | — | EP | claimed |
| WO-2010065446-A2 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2010-06-10 | — | — | WO | claimed |
| US-20100137178-A1 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY | 2010-06-03 | — | — | US | claimed |
| EP-2362765-B1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2020-04-08 | — | — | EP | disclosed |
| US-8431520-B2 | Perfume systems | THE PROCTER & GAMBLE COMPANY (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431520-B2 | Perfume systems | THE PROCTER & GAMBLE COMPANY (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431520-B2 | Perfume systems | THE PROCTER & GAMBLE COMPANY (US) | 2013-04-30 | — | — | US | disclosed |
| US-20130012422-A1 | PERFUME SYSTEMS | SMETS JOHAN (BE) | 2013-01-10 | — | — | US | disclosed |
| US-20130012422-A1 | PERFUME SYSTEMS | SMETS JOHAN (BE) | 2013-01-10 | — | — | US | disclosed |
| US-20130012422-A1 | PERFUME SYSTEMS | SMETS JOHAN (BE) | 2013-01-10 | — | — | US | disclosed |
| WO-2010065446-A2 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20100137178-A1 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY | 2010-06-03 | — | — | US | disclosed |
| US-20100137178-A1 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY | 2010-06-03 | — | — | US | disclosed |
| US-20100137178-A1 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012422-A1 | PERFUME SYSTEMS | TRPA1, PORCN, PLIN5 | LMNA 2578/4885CYP3A4 364/4885ALOX15 544/4885 |
| US-20100137178-A1 | PERFUME SYSTEMS | TRPA1, PORCN, PLIN5 | LMNA 2578/4885CYP3A4 364/4885ALOX15 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.